Molecular Imaging of Lymphoma: Future Directions and Perspectives

More than 250,000 patients die from Hodgkin or non-Hodgkin lymphoma each year. Currently, molecular imaging with 18F-FDG-PET/CT is the standard of care for lymphoma staging and therapy response assessment. In this review, we will briefly summarize the role of molecular imaging for lymphoma diagnosis...

Full description

Saved in:
Bibliographic Details
Published in:Seminars in nuclear medicine 2023-05, Vol.53 (3), p.449-456
Main Authors: Pomykala, Kelsey L., Fendler, Wolfgang P., Vermesh, Ophir, Umutlu, Lale, Herrmann, Ken, Seifert, Robert
Format: Article
Language:English
Subjects:
Artificial Intelligence
Fluorodeoxyglucose F18
Hodgkin Disease - therapy
Humans
Lymphoma - diagnostic imaging
Lymphoma - pathology
Lymphoma - therapy
Molecular Imaging
Neoplasm Staging
Positron Emission Tomography Computed Tomography - methods
Positron-Emission Tomography
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c374t-dcf61caaab13c9dc2c03b6b799174d01326b678cf881f1f6c9d5b360da4d735d3
cites cdi_FETCH-LOGICAL-c374t-dcf61caaab13c9dc2c03b6b799174d01326b678cf881f1f6c9d5b360da4d735d3
container_end_page 456
container_issue 3
container_start_page 449
container_title Seminars in nuclear medicine
container_volume 53
creator Pomykala, Kelsey L.
Fendler, Wolfgang P.
Vermesh, Ophir
Umutlu, Lale
Herrmann, Ken
Seifert, Robert
description More than 250,000 patients die from Hodgkin or non-Hodgkin lymphoma each year. Currently, molecular imaging with 18F-FDG-PET/CT is the standard of care for lymphoma staging and therapy response assessment. In this review, we will briefly summarize the role of molecular imaging for lymphoma diagnosis, staging, outcome prediction, and prognostication. We discuss future directions in response assessment and surveillance with quantitative PET parameters, the utility of interim assessment, and the differences with response assessment to immunomodulatory therapy. Lastly, we will cover innovations in the field regarding novel tracers and artificial intelligence.
doi_str_mv 10.1053/j.semnuclmed.2022.10.003
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2734167237</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0001299822000903</els_id><sourcerecordid>2734167237</sourcerecordid><originalsourceid>FETCH-LOGICAL-c374t-dcf61caaab13c9dc2c03b6b799174d01326b678cf881f1f6c9d5b360da4d735d3</originalsourceid><addsrcrecordid>eNqFkMtOwzAQRS0EoqXwC8hLNgl-xHbCrjwKlYpgAWvLsZ2SKomDnVTq35PQVixZjXTnzIzmAAAxijFi9HYTB1s3va5qa2KCCBniGCF6AqaYsTRKOKGnYIoQwhHJsnQCLkLYIEQYy9g5mFBOk4QSNgXzV1dZ3VfKw2Wt1mWzhq6Aq13dfrla3cFF3_XewsfSW92VrglQNQa-Wx_aMdjacAnOClUFe3WoM_C5ePp4eIlWb8_Lh_kq0lQkXWR0wbFWSuWY6sxoohHNeS6yDIvEIEwJz7lIdZGmuMAFHxiWU46MSoygzNAZuNnvbb377m3oZF0GbatKNdb1QRJBE8wFoWJA0z2qvQvB20K2vqyV30mM5ChQbuSfQDkKHDuDwGH0-nClz8fecfBobADu94Adft2W1sugS9toa34VSePK_6_8ANFphwU</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2734167237</pqid></control><display><type>article</type><title>Molecular Imaging of Lymphoma: Future Directions and Perspectives</title><source>ScienceDirect Freedom Collection</source><creator>Pomykala, Kelsey L. ; Fendler, Wolfgang P. ; Vermesh, Ophir ; Umutlu, Lale ; Herrmann, Ken ; Seifert, Robert</creator><creatorcontrib>Pomykala, Kelsey L. ; Fendler, Wolfgang P. ; Vermesh, Ophir ; Umutlu, Lale ; Herrmann, Ken ; Seifert, Robert</creatorcontrib><description>More than 250,000 patients die from Hodgkin or non-Hodgkin lymphoma each year. Currently, molecular imaging with 18F-FDG-PET/CT is the standard of care for lymphoma staging and therapy response assessment. In this review, we will briefly summarize the role of molecular imaging for lymphoma diagnosis, staging, outcome prediction, and prognostication. We discuss future directions in response assessment and surveillance with quantitative PET parameters, the utility of interim assessment, and the differences with response assessment to immunomodulatory therapy. Lastly, we will cover innovations in the field regarding novel tracers and artificial intelligence.</description><identifier>ISSN: 0001-2998</identifier><identifier>EISSN: 1558-4623</identifier><identifier>DOI: 10.1053/j.semnuclmed.2022.10.003</identifier><identifier>PMID: 36344325</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Artificial Intelligence ; Fluorodeoxyglucose F18 ; Hodgkin Disease - therapy ; Humans ; Lymphoma - diagnostic imaging ; Lymphoma - pathology ; Lymphoma - therapy ; Molecular Imaging ; Neoplasm Staging ; Positron Emission Tomography Computed Tomography - methods ; Positron-Emission Tomography</subject><ispartof>Seminars in nuclear medicine, 2023-05, Vol.53 (3), p.449-456</ispartof><rights>2022 Elsevier Inc.</rights><rights>Copyright © 2022 Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c374t-dcf61caaab13c9dc2c03b6b799174d01326b678cf881f1f6c9d5b360da4d735d3</citedby><cites>FETCH-LOGICAL-c374t-dcf61caaab13c9dc2c03b6b799174d01326b678cf881f1f6c9d5b360da4d735d3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>315,786,790,27957,27958</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36344325$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Pomykala, Kelsey L.</creatorcontrib><creatorcontrib>Fendler, Wolfgang P.</creatorcontrib><creatorcontrib>Vermesh, Ophir</creatorcontrib><creatorcontrib>Umutlu, Lale</creatorcontrib><creatorcontrib>Herrmann, Ken</creatorcontrib><creatorcontrib>Seifert, Robert</creatorcontrib><title>Molecular Imaging of Lymphoma: Future Directions and Perspectives</title><title>Seminars in nuclear medicine</title><addtitle>Semin Nucl Med</addtitle><description>More than 250,000 patients die from Hodgkin or non-Hodgkin lymphoma each year. Currently, molecular imaging with 18F-FDG-PET/CT is the standard of care for lymphoma staging and therapy response assessment. In this review, we will briefly summarize the role of molecular imaging for lymphoma diagnosis, staging, outcome prediction, and prognostication. We discuss future directions in response assessment and surveillance with quantitative PET parameters, the utility of interim assessment, and the differences with response assessment to immunomodulatory therapy. Lastly, we will cover innovations in the field regarding novel tracers and artificial intelligence.</description><subject>Artificial Intelligence</subject><subject>Fluorodeoxyglucose F18</subject><subject>Hodgkin Disease - therapy</subject><subject>Humans</subject><subject>Lymphoma - diagnostic imaging</subject><subject>Lymphoma - pathology</subject><subject>Lymphoma - therapy</subject><subject>Molecular Imaging</subject><subject>Neoplasm Staging</subject><subject>Positron Emission Tomography Computed Tomography - methods</subject><subject>Positron-Emission Tomography</subject><issn>0001-2998</issn><issn>1558-4623</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><recordid>eNqFkMtOwzAQRS0EoqXwC8hLNgl-xHbCrjwKlYpgAWvLsZ2SKomDnVTq35PQVixZjXTnzIzmAAAxijFi9HYTB1s3va5qa2KCCBniGCF6AqaYsTRKOKGnYIoQwhHJsnQCLkLYIEQYy9g5mFBOk4QSNgXzV1dZ3VfKw2Wt1mWzhq6Aq13dfrla3cFF3_XewsfSW92VrglQNQa-Wx_aMdjacAnOClUFe3WoM_C5ePp4eIlWb8_Lh_kq0lQkXWR0wbFWSuWY6sxoohHNeS6yDIvEIEwJz7lIdZGmuMAFHxiWU46MSoygzNAZuNnvbb377m3oZF0GbatKNdb1QRJBE8wFoWJA0z2qvQvB20K2vqyV30mM5ChQbuSfQDkKHDuDwGH0-nClz8fecfBobADu94Adft2W1sugS9toa34VSePK_6_8ANFphwU</recordid><startdate>202305</startdate><enddate>202305</enddate><creator>Pomykala, Kelsey L.</creator><creator>Fendler, Wolfgang P.</creator><creator>Vermesh, Ophir</creator><creator>Umutlu, Lale</creator><creator>Herrmann, Ken</creator><creator>Seifert, Robert</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>202305</creationdate><title>Molecular Imaging of Lymphoma: Future Directions and Perspectives</title><author>Pomykala, Kelsey L. ; Fendler, Wolfgang P. ; Vermesh, Ophir ; Umutlu, Lale ; Herrmann, Ken ; Seifert, Robert</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c374t-dcf61caaab13c9dc2c03b6b799174d01326b678cf881f1f6c9d5b360da4d735d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Artificial Intelligence</topic><topic>Fluorodeoxyglucose F18</topic><topic>Hodgkin Disease - therapy</topic><topic>Humans</topic><topic>Lymphoma - diagnostic imaging</topic><topic>Lymphoma - pathology</topic><topic>Lymphoma - therapy</topic><topic>Molecular Imaging</topic><topic>Neoplasm Staging</topic><topic>Positron Emission Tomography Computed Tomography - methods</topic><topic>Positron-Emission Tomography</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Pomykala, Kelsey L.</creatorcontrib><creatorcontrib>Fendler, Wolfgang P.</creatorcontrib><creatorcontrib>Vermesh, Ophir</creatorcontrib><creatorcontrib>Umutlu, Lale</creatorcontrib><creatorcontrib>Herrmann, Ken</creatorcontrib><creatorcontrib>Seifert, Robert</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Seminars in nuclear medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Pomykala, Kelsey L.</au><au>Fendler, Wolfgang P.</au><au>Vermesh, Ophir</au><au>Umutlu, Lale</au><au>Herrmann, Ken</au><au>Seifert, Robert</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Molecular Imaging of Lymphoma: Future Directions and Perspectives</atitle><jtitle>Seminars in nuclear medicine</jtitle><addtitle>Semin Nucl Med</addtitle><date>2023-05</date><risdate>2023</risdate><volume>53</volume><issue>3</issue><spage>449</spage><epage>456</epage><pages>449-456</pages><issn>0001-2998</issn><eissn>1558-4623</eissn><notes>ObjectType-Article-2</notes><notes>SourceType-Scholarly Journals-1</notes><notes>ObjectType-Feature-3</notes><notes>content type line 23</notes><notes>ObjectType-Review-1</notes><abstract>More than 250,000 patients die from Hodgkin or non-Hodgkin lymphoma each year. Currently, molecular imaging with 18F-FDG-PET/CT is the standard of care for lymphoma staging and therapy response assessment. In this review, we will briefly summarize the role of molecular imaging for lymphoma diagnosis, staging, outcome prediction, and prognostication. We discuss future directions in response assessment and surveillance with quantitative PET parameters, the utility of interim assessment, and the differences with response assessment to immunomodulatory therapy. Lastly, we will cover innovations in the field regarding novel tracers and artificial intelligence.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>36344325</pmid><doi>10.1053/j.semnuclmed.2022.10.003</doi><tpages>8</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0001-2998
ispartof Seminars in nuclear medicine, 2023-05, Vol.53 (3), p.449-456
issn 0001-2998
1558-4623
language eng
recordid cdi_proquest_miscellaneous_2734167237
source ScienceDirect Freedom Collection
subjects Artificial Intelligence
Fluorodeoxyglucose F18
Hodgkin Disease - therapy
Humans
Lymphoma - diagnostic imaging
Lymphoma - pathology
Lymphoma - therapy
Molecular Imaging
Neoplasm Staging
Positron Emission Tomography Computed Tomography - methods
Positron-Emission Tomography
title Molecular Imaging of Lymphoma: Future Directions and Perspectives
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-09-22T07%3A35%3A09IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Molecular%20Imaging%20of%20Lymphoma:%20Future%20Directions%20and%20Perspectives&rft.jtitle=Seminars%20in%20nuclear%20medicine&rft.au=Pomykala,%20Kelsey%20L.&rft.date=2023-05&rft.volume=53&rft.issue=3&rft.spage=449&rft.epage=456&rft.pages=449-456&rft.issn=0001-2998&rft.eissn=1558-4623&rft_id=info:doi/10.1053/j.semnuclmed.2022.10.003&rft_dat=%3Cproquest_cross%3E2734167237%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c374t-dcf61caaab13c9dc2c03b6b799174d01326b678cf881f1f6c9d5b360da4d735d3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2734167237&rft_id=info:pmid/36344325&rfr_iscdi=true